Trials / Terminated
TerminatedNCT05116046
Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia
A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 15 Months – 12 Years
- Healthy volunteers
- Not accepted
Summary
All participants who completed the prior study to assess long-term safety, tolerability, pharmacokinetics and efficacy, and in the opinion of the investigator, continue to have a positive risk:benefit profile, will be offered to enroll in this open-label extension (OLE) study for up to an additional 24 months of treatment. Approximately 63 participants will be offered to continue at the previously received dose of Recifercept either Low Dose Medium Dose High Dose or at the therapeutic dose once it is identified. Participants will attend the clinic monthly for 24 months. Assessments include safety, blood sampling, physical examination, vital signs, anthropometric body measurements \& patient/caregiver quality of life questionnaires.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recifercept | Recifercept |
Timeline
- Start date
- 2021-12-24
- Primary completion
- 2022-12-16
- Completion
- 2023-03-30
- First posted
- 2021-11-10
- Last updated
- 2024-02-08
- Results posted
- 2024-02-08
Locations
14 sites across 7 countries: United States, Australia, Belgium, Denmark, Italy, Portugal, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05116046. Inclusion in this directory is not an endorsement.